ChemoCentryx (CCXI) PT Raised to $64 at Raymond James
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- S&P 500 futures steady after midterm rally; Nasdaq lags on chip weakness
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CCXI Hot Sheet
Price: $11.26 --0%
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 30 | New: 5
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 30 | New: 5
Join SI Premium – FREE
Raymond James analyst Steven Seedhouse raised the price target on ChemoCentryx (NASDAQ: CCXI) to $64.00 (from $56.00) while maintaining a Strong Buy rating.
You May Also Be Interested In
- Agility Robotics goes public on Nasdaq after SPAC merger closes
- Datadog (DDOG) PT Lowered to $260 at Scotiabank
- Goldman Sachs Downgrades Regis Resources Ltd. (RRL:AU) (RGRNF) to Sell
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
